Pleural
Malignant Local Seeding in Procedure Tracts of Pleural Mesothelioma: Incidence and Novel Risk Factors in 308 Patients
Cancers 2025 August 26 [Link] Moshe Lapidot, Emanuele Mazzola, Raphael Bueno Abstract Background/Objectives: Unlike other thoracic malignancies, seeding malignant cells along surgical tracts is a known complication of invasive diagnostic or therapeutic procedures for pleural mesothelioma (PM). We report the tract dissemination rate and risk factors in 308 consecutive patients treated over 9 years in…
Read MoreCombining Chemotherapeutic Agents, Targeted Therapies, Vaccines and Natural Bioactive Compounds for Mesothelioma: Advances and Perspectives
Oncology Research 2025 August 28 [Link] Raffaele Carrano, Carlotta Zucca, Nicla Cristina, Martina Grande, Eleonora Leti Maggio, Riccardo Bei, Antonio Infante, Chiara Focaccetti, Valeria Lucarini, Loredana Cifaldi, Laura Masuelli, Luciano Mutti, Camilla Palumbo, Monica Benvenuto, Roberto Bei Abstract Mesothelioma is a rare and aggressive cancer with a poor prognosis and limited therapeutic options. Despite recent…
Read MorePerioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses
Nature Medicine 2025 September 8 [Link] Joshua E Reuss, Paul K Lee, Reza J Mehran, Chen Hu, Suqi Ke, Amna Jamali, Mimi Najjar, Noushin Niknafs, Jaime Wehr, Ezgi Oner, Qiong Meng, Gavin Pereira, Samira Hosseini-Nami, Mark Sausen, Marianna Zahurak, Richard J Battafarano, Russell K Hales, Joseph Friedberg, Boris Sepesi, Julie S Deutsch, Tricia Cottrell, Janis…
Read MorePleural Mesothelioma: Pathogenesis, Diagnosis, Treatment, Prognosis, and Survival
MedComm 2025 September 1 [Link] Libo Zhang, Meijuan Huang Abstract Pleural mesothelioma (PM) presents significant challenges in clinical management, with current treatment options such as chemotherapy, anti-angiogenic therapies, and immunotherapies only modestly extending progression-free survival (PFS) and overall survival (OS). Another relevant reason is the absence of subsequent-line therapy strategies following progression of PM after…
Read MoreInhibition of YB-1 phosphorylation enhances cisplatin activity and disrupts cell division in pleural mesothelioma
British Journal of Cancer 2025 September 4 [Link] Karin Schelch, Nadine Maach, Muhammad Hashim, Benjamin Zitta, Dominik Kirchhofer, Gerald Timelthaler, Anna Solta, Dominik Emminger, Verena Kopatz, Mir A Hoda, Walter Berger, Clemens Aigner, Balazs Dome, Glen Reid, Michael Grusch Abstract Background: The cold-shock domain protein YB-1 is overexpressed in pleural mesothelioma (PM) and was shown…
Read MoreEvaluation of SOX6 immunohistochemical expression as a diagnostic marker in the distinction of epithelioid mesothelioma from lung carcinomas
Annals of Diagnostic Pathology 2025 August 26 [Link] Fatma Samy Hafez, Safaa Mahmoud Mohamed Abdelkhalek, Shaimaa Abdelraouf Elgohary Abstract Epithelioid mesothelioma (EM) is a pleural malignancy whose many histopathologic patterns may overlap considerably with those of lung adenocarcinoma (LAC) or poorly differentiated squamous cell carcinoma (SCC). This study aimed to evaluate the diagnostic role of…
Read MoreCDKN2A deletion is associated with immune desertification in diffuse pleural mesothelioma
Journal of Experimental & Clinical Cancer Research 2025 August 28 [Link] Federica Torricelli, Benedetta Donati, Veronica Manicardi, Mila Gugnoni, Francesca Reggiani, Gloria Manzotti, Pierluigi Di Chiaro, Cristian Ascione, Simonetta Piana, Riccardo Valli, Roberto Piro, Massimiliano Paci, Nicola Facciolongo, Filippo Lococo, Alessia Ciarrocchi Abstract Introduction: Diffuse Pleural Mesothelioma (DPM) is a rare and incurable cancer. Immune…
Read MoreIdentification of Cembrane Diterpenoids from Sinularia sp. That Reduce the Viability of Diffuse Pleural Mesothelioma Cell Lines
Journal of Natural Products 2025 August 25 [Link] Maria Orfanoudaki, Anam F Shaikh, Dongdong Wang, Vivek Singh, Lin Du, Jennifer A Wilson, Antony Wamiru, Ekaterina I Goncharova, Nathanael Pruett, Chuong D Hoang, Brice A P Wilson, Barry R O’Keefe Abstract Diffuse pleural mesothelioma (DPM) is a rare but aggressive late-onset cancer. A high-throughput screen of…
Read MoreIdentification of Cembrane Diterpenoids from Sinularia sp. That Reduce the Viability of Diffuse Pleural Mesothelioma Cell Lines
Journal of Natural Products 2025 August 25 [Link] Maria Orfanoudaki, Anam F Shaikh, Dongdong Wang, Vivek Singh, Lin Du, Jennifer A Wilson, Antony Wamiru, Ekaterina I Goncharova, Nathanael Pruett, Chuong D Hoang, Brice A P Wilson, Barry R O’Keefe Abstract Diffuse pleural mesothelioma (DPM) is a rare but aggressive late-onset cancer. A high-throughput screen of…
Read MorePartial Response to Nivolumab and Ipilimumab in a Patient With Malignant Pleural Mesothelioma and Pre-Existing Myasthenia Gravis Without Severe Flares or Immune-Related Adverse Events: A Case Report
Respirology Case Reports 2025 August 19 [Link] Mariko Higa, Tomoya Kuda, Yuichiro Ohya, Hidenori Kawasaki Abstract Detailed clinical data on the combination immune checkpoint inhibitor (ICI) therapy in patients with myasthenia gravis (MG) remain limited. We report a case of malignant pleural mesothelioma with previously undiagnosed ocular MG. Owing to hepatic dysfunction, reduced doses of…
Read More